Protocol Abstract and Schema
|
|
- Bernice Webster
- 6 years ago
- Views:
Transcription
1 NCI Prtcl #: PBTC-042 Lcal Prtcl #: PBTC-042 Prtcl Abstract and Schema PBTC-042: Phase I study f CDK 4-6 inhibitr PD (palbciclib; IBRANCE) in children with recurrent, prgressive r refractry central nervus system tumrs Descriptin This is a multicenter, Phase I trial fr children with Retinblastma Prtein 1 (Rb1) psitive recurrent, prgressive r refractry central nervus system tumrs. In the recent years there have been several clinical trials in adults with cancer utilizing small mlecule inhibitrs targeting cell cycle regulatry genes such as CDKs (cyclin-dependent kinase). In nrmal cells, these kinases are kept under cntrl by a gene, hwever, this gene is frequently deleted in cancers and these tw kinases are uncntrllably activated which drives the cell t divide and frm cancer. This trial is using PD (palbciclib; IBRANCE), a selective CDK inhibitr, t be evaluated in children with CNS tumrs. PD (Pfizer Crpratin, USA) is an rally active, water sluble, cell-permeable highly specific inhibitr f CDK4 and 6. It is designed t shut dwn the activity f mlecules, CDK4 and 6 that drive cell divisin. PD is expected t wrk nly if the cancer cells demnstrate expressin f the tumr suppressr retinblastma (Rb1) prtein which is needed t cntrl cell grwth even if CDK4/6 is inhibited. A screening test fr presence r absence f Rb1 will therefre be perfrmed in all types f CNS tumrs except diffuse pntine glima (DIPG), medullblastma, r Atypical Teratid Rhabdid Tumr (ATRT) t cnfirm eligibility fr this trial. Ratinale: Survival fr children with recurrent CNS tumrs is dismal and nvel therapeutic ptins need t be develped in rder t imprve utcme. Cancer initiatin and prgressin is dependent n deregulatin f the cmpnents and phases f the cell cycle. Ample evidence exists n alteratins f CDKs, Cyclins, cell cycle inhibitrs, and checkpint prteins in pediatric CNS tumrs. The presence f specific mutatins in the prteins invlved in G1-S phase transitin f the cell cycle in these tumrs is particularly relevant fr the use f a specific CDK4/6 inhibitr like PD Furthermre, it is likely that ver 60% f pediatric CNS tumrs are likely t have intact Rb-prtein, a pre-requisite fr the efficacy f this cell cycle inhibitr. PD has nt been tested in children with cancer thus far. A Phase I study is therefre needed t assess the txicity, MTD, pharmackinetics, and preliminary evidence f efficacy f this agent in this patient ppulatin. Since myelsuppressin is the predminant side effect f this agent, the Phase I study will first evaluate the txicities in children wh have nt been heavily pre-treated previusly. With the MTD identified in less-heavily pre-treated patients (stratum I), this phase I study will be expanded t include heavily pre-treated patients (defined as thse wh have received mre than 4 prir regimens (either myelsuppressive chemtherapy r bilgic) ± cranispinal irradiatin ± myelablative chemtherapy plus stem cell rescue) in a separate chrt (stratum II). Treatment f these patients will be initiated at 50 mg/m 2 /day (ne dse level belw the ptential MTD in stratum I) as the starting dse level. Stratum II is likely t mstly include patients with recurrent medullblastma, ther central PNETs, ATRT, and germ cell tumrs. Recent genmic studies f medullblastma and ATRT have demnstrated that Rb1 prtein is intact in these tumrs. Therefre, patients with medullblastma r ATRT will nt be required t have their tumrs screened fr Rb1 expressin. Versin 7.0 1
2 NCI Prtcl #: PBTC-042 Lcal Prtcl #: PBTC-042 Schema This is a dse escalatin trial f PD t determine the maximum tlerated dse in children with recurrent brain tumrs. PD is taken rally nce a day fr 21 days fllwed by a week rest. One curse is therefre equivalent t 28 days. Therapy may cntinue fr up t tw years (26 curses) in the absence f disease prgressin r unacceptable txicity. Dsing is based n BSA calculated at the beginning f each curse. The starting dse is 50 mg/m 2 fr stratum I and stratum II. PD dse escalatins will be perfrmed accrding t the table belw until the maximum tlerated r recmmended Phase II dse is reached. Since myelsuppressin is the main dse limiting txicity (DLT) f this drug, patients wh have been mre heavily pretreated are likely t experience hematlgic txicity with this agent. Therefre, patients will be divided int tw strata; stratum I- patients wh have received either fcal raditherapy (RT) nly r fcal RT ± 4 prir myelsuppressive chemtherapy and/ r bilgic therapy regimens r stratum II- thse wh have received > 4 prir regimens (either chemtherapy r bilgic agent), ± cranispinal irradiatin, and ± myelablative chemtherapy plus bne marrw r peripheral bld stem cell rescue. Enrllment t Stratum I is currently nging and has accrued 12 patients at dse level 1 (n=3), 2 (n=3), and 3 (n=6). Tw patients enrlled at dse level 3 were inevaluable fr DLT. Of the 10 evaluable patients, 2 f 4 patients at dse level 3 experienced a DLT f grade 4 neutrpenia. Hence the MTD was exceeded at dse level 3, and 3 additinal patients have been enrlled at dse level 2. The maximum tlerated dse (MTD) fr stratum I is expected t be dse level 2 (75 mg/m 2 /day fr 21 days). Since the pssibility f myelsuppressin is expected t be mre in patients enrlled in stratum II (heavily pretreated patients), we cnsider it mre prudent t cmmence enrllment f patients at dse level 1 which is 50 mg/m 2 /day. An MTD will be separately determined fr this stratum. Stratum I and II - PD (IBRANCE) Dsing Regimen and BSA Restrictins Dse Level Dse (mg/m 2 ) BSA (m 2 ) 1* ** *Starting dse fr stratum II ** Current enrllment fr stratum I OBJECTIVES Primary Objectives T determine the maximum tlerated dse (MTD)/Phase II recmmended dse and describe txicities related t PD in children with Retinblastma Prtein 1 (Rb1) psitive recurrent, prgressive, r refractry primary CNS tumrs. MTD will be determined separately in less-heavily pre-treated vs. heavily pre-treated patients. T determine plasma pharmackinetics f PD in children with Rb1 psitive recurrent, prgressive r refractry primary CNS tumrs Secndary Objectives T recrd preliminary evidence f efficacy f PD in children with recurrent CNS tumrs T evaluate CDK4/6, cyclin D1-3, Ink4a-ARF cpy-number variatins in available tumr tissue by array cmparative, genmic hybridizatin (acgh) Versin 7.0 2
3 NCI Prtcl #: PBTC-042 Lcal Prtcl #: PBTC-042 T explre the ptential relatinships between the pharmackinetics f PD and pharmacdynamic respnse (e.g. percentage change in abslute neutrphil cunt (ANC), platelet cunts) T explre the pharmacgenetic plymrphisms in PD metablizing enzymes and transprters and relate these plymrphisms t PD pharmackinetics PATIENT SELECTION Screening Criteria All subjects must meet the fllwing criteria withut exceptin. Screening Cnsent Patients wh are candidates fr enrllment are willing t sign a screening cnsent and prvide pre-trial tumr material fr Rb1 testing. Screening applies t patients with all types f CNS tumrs except DIPG, medullblastma, r ATRT. Tumr Patients must have recurrent, prgressive r refractry central nervus system (CNS) tumrs. Patients with secndary malignant glimas will be eligible fr this study but shuld cnfrm t the strict prir treatment expsure criteria irrespective f the number f individual tumrs treated previusly. Patients with lw grade glimas are excluded. Prir Therapy Stratum I: Less-Heavily Pretreated Stratum Patients wh have received the fllwing: 4 prir treatment regimens* with either myelsuppressive chemtherapy r bilgic agents and/r fcal raditherapy Stratum II: Heavily Pretreated Stratum Patients wh have received the fllwing: 4 prir treatment regimens* with either myelsuppressive chemtherapy r bilgic agents and/r cranispinal irradiatin and/r myelablative chemtherapy with autlgus stem cell rescue *A treatment regimen is defined as a single agent (chemtherapeutic r bilgic), r a sequential cmbinatin f therapies that can include raditherapy (with r withut cncurrent radisensitizer, chemtherapy, r bilgic therapy) fllwed by maintenance therapy (either single r cmbinatin) given ver a perid f time at either diagnsis r relapse. Age Patient must be 4 years and 21 years f age. Patient must be able t swallw capsules. Pre-Trial Tumr Tissue availability Frmalin fixed paraffin embedded tumr tissue (preferably frm the mst recent recurrence) must be available t assess Rb1 prtein status prir t enrllment. Only Versin 7.0 3
4 NCI Prtcl #: PBTC-042 Lcal Prtcl #: PBTC-042 patients with recurrent diffuse intrinsic brain stem glima (DIPG), medullblastma, r ATRT can be enrlled withut the need fr available tumr tissue fr Rb1 prtein status cnfirmatin. BSA: Patients enrlled n dse level 1 (50mg/m2) must have BSA 1.20m2 Patients enrlled n dse level 2 (75mg/m2) must have BSA 0.93m2 Patients enrlled n dse level 3 (95mg/m2) must have BSA 0.70m2 Eligibility fr Treatment Criteria All subjects must meet the fllwing inclusin and exclusin criteria. N exceptins will be given. Eligible Diagnsis Tumr type: Histlgically cnfirmed retinblastma prtein (Rb1) psitive primary recurrent, prgressive, r refractry central nervus system tumrs. Patients with lw grade glimas are excluded. Frmalin fixed paraffin embedded tumr tissue (preferably frm the mst recent recurrence) must be available t assess Rb1 prtein status prir t enrllment. Patients with recurrent diffuse intrinsic brain stem glima (DIPG), medullblastma, r ATRT can be enrlled withut the need fr available tumr tissue fr Rb1 prtein status cnfirmatin. Measureable Disease Patients must have measurable disease (in 2-dimensins) n MRI scan f brain and/r spine t assess preliminary evidence f respnse. Age BSA: Patient must be 4 years and 21 years f age at the time f enrllment. Patients enrlled n dse level 1 (50mg/m2) must have BSA 1.20m2 Patients enrlled n dse level 2 (75mg/m2) must have BSA 0.93m2 Patients enrlled n dse level 3 (95mg/m2) must have BSA 0.70m2 Prir Therapy - Stratum I: Less-Heavily Pretreated Stratum Patients wh have received the fllwing: 4 prir treatment regimens* with either myelsuppressive chemtherapy r bilgic agents and/r fcal raditherapy. - Stratum II: Heavily Pretreated Stratum Patients wh have received the fllwing: > 4 prir treatment regimens* with either myelsuppressive chemtherapy r bilgic agents and/r cranispinal irradiatin and/r myelablative chemtherapy with autlgus stem cell rescue Versin 7.0 4
5 NCI Prtcl #: PBTC-042 Lcal Prtcl #: PBTC-042 *A treatment regimen is defined as a single agent (chemtherapeutic r bilgic), r a sequential cmbinatin f therapies that can include raditherapy (with r withut cncurrent radisensitizer, chemtherapy, r bilgic therapy) fllwed by maintenance therapy (either single r cmbinatin) given ver a perid f time at either diagnsis r relapse. Patients must have fully recvered frm the acute treatment- related txicities f all prir therapies prir t entering this study. Fr thse acute baseline adverse events attributable t prir therapy, patients must meet rgan functin criteria (sectin ) in the Inclusin and Exclusin Criteria. Chemtherapy: Patients must have received their last dse f knwn myelsuppressive anticancer chemtherapy at least three (3) weeks prir t enrllment in the study r at least six (6) weeks fr thse receiving nitrsurea. Bne marrw/stem Cell Infusin: 3 mnths since autlgus bne marrw/stem cell infusin prir t enrllment (stratum II nly) Bilgic therapy: Patients shuld have received their last dse f bilgic agent 7 days prir t enrllment. In the event the patient has received anther bilgic agent and has experienced Grade 2 myelsuppressin, then at least three (3) weeks must have elapsed prir t enrllment. If the investigatinal r bilgic agent has a prlnged half-life then at least three (3) weeks interval is required. Fr patients n mnclnal antibdies including Bevacizumab, please refer t list f half-lives available n the PBTC webpage under Generic Frms and Templates. Raditherapy: Patients must have had their last fractin f: Fcal irradiatin > 2 weeks prir t enrllment Cranispinal irradiatin > 3 mnths prir t enrllment (stratum II nly) Crticsterids: Patients wh are receiving dexamethasne r ther crticsterids must be n a stable r decreasing dse fr at least 1 week prir t enrllment. It is recmmended that patients be ff all sterid therapy r receive the least dse that will cntrl their neurlgic symptms Grwth factrs: All clny frming grwth factr(s) have been discntinued fr at least ne week prir t enrllment (filgrastim, sargramstim, and erythrpietin). Fr patients n lng acting grwth factrs, the interval shuld be tw weeks. Inclusin f Wmen and Minrities Bth males and females f all races and ethnic grups are eligible fr this study. Neurlgic Status Patients with neurlgical deficits that are stable fr a minimum f ne week prir t enrllment. Patients must be able t swallw capsules. Perfrmance Status Karnfsky Perfrmance Scale (KPS fr > 16 years f age) r Lansky Perfrmance Scre (LPS fr 16 years f age) assessed within tw weeks f enrllment must be 60. Versin 7.0 5
6 NCI Prtcl #: PBTC-042 Lcal Prtcl #: PBTC-042 Organ Functin Patients must have nrmal rgan and marrw functin as defined belw: Abslute neutrphil cunt >1,000/mm3 Platelets >100,000/ mm3 transfusin independent (n platelet transfusin ne week prir t enrllment ) Hemglbin 8g/dl Ttal bilirubin 1.5 times upper limit f institutinal nrmal (ULN) fr age AST (SGOT)/ALT(SGPT) < 3 x institutinal upper limit f nrmal fr age Serum albumin 3g/dL Creatinine clearance r radiistpe GFR 70 ml/min/1.73 m2 r a serum creatinine based n age/gender as fllws: Serum Creatinine fr age/gender Age Maximum Serum Creatinine (mg/dl) Male Female 1 t < 2 years t < 6 years t < 10 years t < 13 years t < 16 years years The threshld creatinine values in this Table were derived frm the Schwartz frmula fr estimating GFR (Schwartz et al. J. Peds, 106:522, 1985) utilizing child length and stature data published by the CDC. Pregnancy Status Female patients f childbearing ptential must have a negative serum pregnancy test at the time f enrllment. Pregnancy Preventin Patients f childbearing r child fathering ptential must agree t use adequate cntraceptive methds while being treated n this study and fr 97 days after cmpleting therapy. Infrmed Cnsent Patient and/r guardian have the ability t understand and the willingness t sign a written infrmed cnsent dcument accrding t institutinal guidelines. Versin 7.0 6
7 NCI Prtcl #: PBTC-042 Lcal Prtcl #: PBTC-042 Exclusin Criteria Patients with any clinical significant unrelated systemic illness (serius infectins r significant cardiac, pulmnary, hepatic r ther rgan dysfunctin) that is likely t interfere with the study prcedures r results Patients with lw grade glimas and Rb1 negative tumrs Patients with QTc interval f > 450 msec r thse n medicatins knwn t prlng QTc interval (see Errr! Reference surce nt fund.) Prir treatment n a CDK inhibitr (e.g. Flavpiridl) Patients wh are receiving drugs that are strng inducers r inhibitrs f CYP3A4 (seeerrr! Reference surce nt fund.) Patients wh are receiving any ther investigatinal therapy Patients wh require enzyme inducing anti-cnvulsants t cntrl seizures Patients with cataracts n phthalmlgic examinatin. The phthalmlgy reprt frm the institutin shuld clearly specify the presence r absence f cataracts per slit lamp examinatin. Versin 7.0 7
PBTC-026: A Feasibility Study of SAHA Combined with Isotretinoin and Chemotherapy in Infants with Embryonal Tumors of the Central Nervous System
PBTC-026: A Feasibility Study f SAHA Cmbined with Istretinin and Chemtherapy in Infants with Embrynal Tumrs f the Central Nervus System PURPOSE: This clinical trial is studying the side effects f giving
More informationWARNING: FATAL AND SERIOUS TOXICITIES: SEVERE DIARRHEA AND CARDIAC TOXICITIES
INDICATION FARYDAK (panbinstat) capsules, a histne deacetylase inhibitr, in cmbinatin with brtezmib and dexamethasne, is indicated fr the treatment f patients with multiple myelma wh have received at least
More informationNCI Version Date: (194) NSABP B-55/BIG 6-13
Figure 1 Study Flw Chart ICF fr patients with unknwn BRCA status t underg central BRCA testing during, r prir t, neadjuvant/adjuvant chemtherapy Neadjuvant chemtherapy Minimum 6 cycles (cntaining anthracyclines,
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial infrmatin prvided in this public disclsure synpsis is supplied fr infrmatinal purpses nly. Please nte that the results reprted in any single trial may nt reflect the verall ptential
More informationA Phase I Study of CEP-701 in Patients with Refractory Neuroblastoma NANT (01-03) A New Approaches to Neuroblastoma Therapy (NANT) treatment protocol.
SAMPLE INFORMED CONSENT A Phase I Study f CEP-701 in Patients with Refractry Neurblastma NANT (01-03) A New Appraches t Neurblastma Therapy (NANT) treatment prtcl. The wrd yu used thrughut this dcument
More informationFrequently Asked Questions: IS RT-Q-PCR Testing
Questins 1. What is chrnic myelid leukemia (CML)? 2. Hw des smene knw if they have CML? 3. Hw is smene diagnsed with CML? Frequently Asked Questins: IS RT-Q-PCR Testing Answers CML is a cancer f the bld
More informationPage 1 of 5. Fast Facts. CTC v.4; AJCC 7 th ed. Herceptin provided
Page 1 f 5 NSABP B-47 - A Randmized Phase III Trial f Adjuvant Therapy Cmparing Chemtherapy Alne (Six Cycles f Dcetaxel Plus Cyclphsphamide r Fur Cycles f Dxrubicin Plus Cyclphsphamide Fllwed by Weekly
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synpsis fr Public Disclsure This clinical study synpsis is prvided in line with Behringer Ingelheim s Plicy n Transparency and Publicatin f Clinical Study Data. The synpsis which is
More informationRituxan (rituximab) Effective Date: 10/01/2015. Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage
Rituxan (rituximab) Line(s) f Business: HMO; PPO; QUEST Integratin Akamai Advantage Effective Date: 10/01/2015 POLICY A. INDICATIONS The indicatins belw including FDA-apprved indicatins and cmpendial uses
More informationUS Public Health Service Clinical Practice Guidelines for PrEP
Webcast 1.3 US Public Health Service Clinical Practice Guidelines fr PrEP P R E S ENTED BY: M A R K T H R U N, M D A S S O C I AT E P R O F E S S O R, U N I V E R S I T Y O F C O L O R A D O, D I V I S
More informationStudy Design Open, three arm-stratified, non-randomized, prospective, multicentric study
PONS Study Synpsis Title f the Study Subtype-Stratified Fllw-up Care Study f Breast Cancer Patients with Cmbined In Vitr and In Viv Diagnstics Plus Early Target-Oriented Interventin Gals Imprve and individualize
More informationITP typically presents with the sudden appearance of a petechial rash, spontaneous bruising and/or bleeding in an otherwise well child.
Acute Immune Thrmbcytpenia Purpura (ITP) Backgrund Primary immune thrmbcytpenia (ITP) is an acquired immune mediated disrder characterised by islated thrmbcytpenia, defined as a peripheral bld platelet
More informationCommissioning Policy: South Warwickshire CCG (SWCCG)
Cmmissining Plicy: Suth Warwickshire CCG (SWCCG) Treatment Indicatin Criteria FreeStyle Libre Flash Cntinuus Glucse Mnitring System Type I Diabetes Prir apprval must be requested frm the Individual Funding
More informationSignificance of Chronic Kidney Disease in 2015
1 Significance f Chrnic Kidney Disease in 2015 There is still a requirement within QOF t keep a register f peple with CKD stages 3-5. The ther CKD QOF targets have been retired. This is because CKD care
More informationBRCA1 and BRCA2 Mutations
BRCA1 and BRCA2 Mutatins ROBERT LEVITT, MD JESSICA BERGER-WEISS, MD ADRIENNE POTTS, MD HARTAJ POWELL, MD, MPH COURTNEY LEVENSON, MD LAUREN BURNS, MSN, RN, WHNP OBGYNCWC.COM v Cancer is a cmplex disease
More informationSERVICE DE GYNÉCOLOGIE-ONCOLOGIE PROTOCOLES EN RECRUTEMENT
SERVICE DE GYNÉCOLOGIE-ONCOLOGIE PROTOCOLES EN RECRUTEMENT OVAIRES PROTOCOLES PTES PHASE DESCRIPTION OV25 DP/GSO/GSO/FG 6 II PRÉVENTION A Randmized Phase II Duble-Blind Placeb-Cntrlled Trials f Acetylsalicylic
More informationP02-03 CALA Program Description Proficiency Testing Policy for Accreditation Revision 1.9 July 26, 2017
P02-03 CALA Prgram Descriptin Prficiency Testing Plicy fr Accreditatin Revisin 1.9 July 26, 2017 P02-03 CALA Prgram Descriptin Prficiency Testing Plicy fr Accreditatin TABLE OF CONTENTS TABLE OF CONTENTS...
More informationXX Abraxane 100 MG SUSR (CELGENE CORP)
Plicy Medical Plicy Manual Apprved: D Nt Implement Until 1/31/19 Paclitaxel (Prtein-Bund) NDC CODE(S) 68817-0134-XX Abraxane 100 MG SUSR (CELGENE CORP) DESCRIPTION Paclitaxel is a natural prduct with antitumr
More informationBenefits for Anesthesia Services for the CSHCN Services Program to Change Effective for dates of service on or after July 1, 2008, benefit criteria
Benefits fr Anesthesia Services fr the CSHCN Services Prgram t Change Effective fr dates f service n r after July 1, 2008, benefit criteria fr anesthesia will change fr the Children with Special Health
More informationACRIN 6666 Screening Breast US Follow-up Assessment Form
Screening Breast US Fllw-up Assessment Frm N. Instructins: The frm is cmpleted at 12, 24 and 36 mnths pst initial n study mammgraphy and ultrasund by the Radilgist r RA. Reprt all interim infrmatin related
More informationNew Exception Status Benefits
FEBRUARY 2019 Nva Sctia Frmulary Updates New Exceptin Status Benefits Prcysbi (cysteamine bitartrate) Nucala (meplizumab) Ocaliva (betichlic acid) Ravicti (glycerl phenylbutyrate) Taltz (ixekizumab) Criteria
More informationReferral Criteria: Inflammation of the Spine Feb
Referral Criteria: Inflammatin f the Spine Feb 2019 1 5.7. Inflammatin f the Spine Backgrund Ankylsing spndylitis and axial spndylarthrpathy are fund in arund 0.3-1.2% f the ppulatin. Spndylarthritis encmpasses
More informationRequest for Prior Authorization for Click here to enter text. Website Form Submit request via: Fax
Request fr Prir Authrizatin fr Click here t enter text. Website Frm www.highmarkhealthptins.cm Submit request via: Fax - 1-855-476-4158 Updated: 05/2018 DMMA Apprved: 05/2018 All requests fr Intravenus
More informationCONSENT FOR KYBELLA INJECTABLE FAT REDUCTION
CONSENT FOR KYBELLA INJECTABLE FAT REDUCTION INSTRUCTIONS This is an infrmed cnsent dcument which has been prepared t help yur Dctr infrm yu cncerning fat reductin with an injectable medicatin, its risks,
More informationBreast Cancer Awareness Month 2018 Key Messages (as of June 6, 2018)
Breast Cancer Awareness Mnth 2018 Key Messages (as f June 6, 2018) In this dcument there are tw sectins f messages in supprt f Cancer Care Ontari s Breast Cancer Awareness Mnth 2018: 1. Campaign key messages
More informationCDC Influenza Division Key Points MMWR Updates February 20, 2014
CDC Influenza Divisin Key Pints MMWR Updates In this dcument: Summary Key Messages Seasnal Influenza Vaccine Effectiveness: Interim Adjusted Estimates Influenza Surveillance Update: September 29, 2013-February
More informationAnnex III. Amendments to relevant sections of the Product Information
Changes t the Prduct infrmatin as apprved by the CHMP n 13 Octber 2016, pending endrsement by the Eurpean Cmmissin Annex III Amendments t relevant sectins f the Prduct Infrmatin Nte: These amendments t
More informationContinuous Quality Improvement: Treatment Record Reviews. Third Thursday Provider Call (August 20, 2015) Wendy Bowlin, QM Administrator
Cntinuus Quality Imprvement: Treatment Recrd Reviews Third Thursday Prvider Call (August 20, 2015) Wendy Bwlin, QM Administratr Gals f the Presentatin Review the findings f Treatment Recrd Review results
More informationSolid Organ Transplant Benefits to Change for Texas Medicaid
Slid Organ Transplant Benefits t Change fr Texas Medicaid Infrmatin psted February 13, 2015 Nte: All new and updated prcedure cdes and their assciated reimbursement rates are prpsed benefits pending a
More informationMeasure Specific Guidelines for Comprehensive Diabetes Care (CDC)
Measure Specific Guidelines fr Cmprehensive Diabetes Care (CDC) Descriptin: Members age 18-75 years f age with diabetes (Type 1 and Type 2)* that had all f the fllwing: *Members in hspice are excluded
More informationOntario s Referral and Listing Criteria for Adult Lung Transplantation
Ontari s Referral and Listing Criteria fr Adult Lung Transplantatin Versin 2.0 Trillium Gift f Life Netwrk Adult Lung Transplantatin Referral & Listing Criteria PATIENT REFERRAL CRITERIA: The patient referral
More informationXX Abraxane 100 MG SUSR (CELGENE CORP
Medical Manual Apprved Revised: D Nt Implement until 6/30/2019 Paclitaxel (Prtein-Bund) NDC CODE(S) 68817-0134-XX Abraxane 100 MG SUSR (CELGENE CORP DESCRIPTION Paclitaxel is a natural prduct with antitumr
More informationFolotyn (pralatrexate)
Fltyn (pralatrexate) Line(s) f Business: HMO; PPO; QUEST Integratin Akamai Advantage Original Effective Date: 10/01/2015 Current Effective Date: 01/01/2018TBD03/01/2017 POLICY A. INDICATIONS The indicatins
More informationHEALTH SURVEILLANCE INDICATORS: CERVICAL CANCER SCREENING. Public Health Relevance. Highlights.
HEALTH SURVEILLANCE INDICATORS: CERVICAL CANCER SCREENING Public Health Relevance Cervical cancer is 90% preventable by having regular Papaniclau (Pap) tests. The Pap test, als knwn as a cervical smear,
More informationFTD RESEARCH: The Value of Studies and Opportunities for Involvement
FTD RESEARCH: The Value f Studies and Opprtunities fr Invlvement Sarah Lawrence, MS Research Prgram Manager Ann Fishman, MBA Sr. Research Crdinatr Weiyi Mu, ScM Genetic Cunselr Suzanne Dana Spuse/Caregiver
More informationBP Thresholds for Medical Review
BP Threshlds fr Medical Review Wmen presents t GP pstnatally with high bld pressure r referred t GP by midwife GP t review patient n the same day if BP>150/100. If BP (dne by midwife) persistently 140-149/90-99,
More informationBedfordshire and Hertfordshire DRAFT Priorities forum statement Number: Subject: Prostatism Date of decision: January 2010 Date of review:
Bedfrdshire and Hertfrdshire DRAFT Pririties frum statement Number: Subject: Prstatism Date f decisin: January 2010 Date f review: Referral criteria Mst men with lwer urinary tract symptms due t benign
More informationCDC Influenza Technical Key Points February 15, 2018
CDC Influenza Technical Key Pints In this dcument: Summary Key Pints U.S. Vaccine Effectiveness U.S. Flu Activity Update Summary Key Pints On Thursday, tw influenza-related reprts appeared in the Mrbidity
More informationChildhood Immunization Status (NQF 0038)
Childhd Immunizatin Status (NQF 0038) EMeasure Name Childhd Immunizatin EMeasure Id Pending Status Versin Number 1 Set Id Pending Available Date N infrmatin Measurement Perid January 1, 20xx thrugh December
More informationService Change Process. Gateway 1 High-level Proposition. Innovation project name: Patient Self-Monitoring/Management of Warfarin
Service Change Prcess Gateway 1 High-level Prpsitin Innvatin prject name: Patient Self-Mnitring/Management f Warfarin NHS Bury Please describe the service change being prpsed. Please describe what service(s)
More informationSwindon Joint Strategic Needs Assessment Bulletin
Swindn Jint Strategic Needs Assessment Bulletin Swindn Diabetes 2017 Key Pints: This JSNA gives health facts abut peple with diabetes r peple wh might get diabetes in Swindn. This helps us t plan fr medical
More informationiprex Fact Sheet: Key Results
EMBARGOED UNTIL RELEASE Tuesday, 23 Nvember 2010, 8 a.m. EST CONTACT Mark Aurigemma; 646-270-9451; mark@aucmm.net Pedr Gicchea; 415-490-8350 pgicchea@gladstne.ucsf.edu iprex Fact Sheet: Key Results iprex
More information23/11/2015. Introduction & Aims. Methods. Methods. Survey response. Patient Survey (baseline)
Intrductin & Aims Drug and Alchl Cnsultatin Liaisn (AOD CL) services aim t imprve identificatin and treatment f patients with AOD mrbidity. The csts and cnsequences f targeting AOD patients presenting
More informationField Epidemiology Training Program
Field Epidemilgy Training Prgram Cancer Curriculum: Principles f Cancer Registries Case Study: Hspital-Based Cancer Registries FACILITATOR GUIDE FETP Cancer Curriculum: Principles f Cancer Registries Case
More informationAppendix C Guidelines for treating status epilepticus in adults and children
Appendix C Guidelines fr treating status epilepticus in adults and children 1.1 Treating cnvulsive status epilepticus in adults General measures 1st stage (0 10 minutes) Secure airway and resuscitate Administer
More information1.11 INSULIN INFUSION PUMP MANAGEMENT INPATIENT
WOMEN AND NEWBORN HEALTH SERVICE CLINICAL GUIDELINES SECTION A: GUIDELINES RELEVANT TO OBSTETRICS AND GYNAECOLOGY 1 STANDARD PROTOCOLS 1.11 INSULIN INFUSION PUMP MANAGEMENT - INPATIENT Authrised by: OGCCU
More informationPerjeta (pertuzumab) Document Number: IC I. Length of Authorization. Dosing Limits. Initial Approval Criteria
Perjeta (pertuzumab) Last Review Date: 11/21/2017 Date f Origin: 11/01/2012 Dcument Number: IC-0096 Dates Reviewed: 12/2012, 3/2013, 6/2013, 9/2013, 11/2013, 12/2013, 3/2014, 6/2014, 9/2014, 12/2014, 3/2015,
More information2017 Optum, Inc. All rights reserved BH1124_112017
1) What are the benefits t clients f encuraging the use f MAT? Withut MAT, 90% f individuals with Opiid Use Disrder (OUD) will relapse within ne year. With MAT, the relapse rate fr thse with OUD decreases
More informationTOP TIPS Lung Cancer Update Dr Andrew Wight Consultant respiratory Physician - WUTH
Tpic Circulatin list In case f query please cntact Executive Summary TOP TIPS Lung Cancer Update Dr Andrew Wight Cnsultant respiratry Physician - WUTH All Wirral GP s JaneFletcher2@nhs.net Dear Clleagues,
More informationYescarta (axicabtagene ciloleucel) (Intravenous)
Yescarta (axicabtagene cilleucel) (Intravenus) Last Review Date: 10/31/2017 Date f Origin: 10/31/2017 Dates Reviewed: 10/2017 Dcument Number: IC-0333 I. Length f Authrizatin Cverage will be prvided fr
More informationChronic Fatigue Syndrome
Chrnic Fatigue Syndrme (Als knwn as Myalgic encephalmyelitis/encephalmyelpathy) What is CFS/ME? CFS/ME cmprises a range f symptms that include fatigue, malaise, headaches, sleep disturbances, difficulties
More informationQ 5: Is relaxation training better (more effective than/as safe as) than treatment as usual in adults with depressive episode/disorder?
updated 2012 Relaxatin training Q 5: Is relaxatin training better (mre effective than/as safe as) than treatment as usual in adults with depressive episde/disrder? Backgrund The number f general health
More informationClinical Study Synopsis
Clinical Study Synpsis This Clinical Study Synpsis is prvided fr patients and healthcare prfessinals t increase the transparency f Bayer's clinical research. This dcument is nt intended t replace the advice
More informationAnnual Principal Investigator Worksheet About Local Context
Cmpleting the NCI CIRB Annual Principal Investigatr Wrksheet Abut Lcal Cntext and the Study-Specific Wrksheet Abut Lcal Cntext at the University f Iwa All investigatrs cnducting research with the Natinal
More informationSafety of HPV vaccination: A FIGO STATEMENT
FIGO Statement n HPV Vaccinatin Safety, August 2nd, 2013 Safety f HPV vaccinatin: A FIGO STATEMENT July, 2013 Human papillmavirus vaccines are used in many cuntries; glbally, mre than 175 millin dses have
More informationStructured Assessment using Multiple Patient. Scenarios (StAMPS) Exam Information
Structured Assessment using Multiple Patient Scenaris (StAMPS) Exam Infrmatin 1. Preparing fr the StAMPS assessment prcess StAMPS is an assessment mdality that is designed t test higher rder functins in
More information2017 CMS Web Interface
CMS Web Interface PREV-5 (NQF 2372): Breast Cancer Screening Measure Steward: NCQA Web Interface V1.0 Page 1 f 18 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE SAMPLING INFORMATION... 4 BENEFICIARY
More informationOsteoporosis Fast Facts
Osteprsis Fast Facts Fast Facts n Osteprsis Definitin Osteprsis, r prus bne, is a disease characterized by lw bne mass and structural deteriratin f bne tissue, leading t bne fragility and an increased
More information1.6. Topic 1: Cell Biology (Teacher) Essential Idea: Cell division is essential but must be controlled. 1.6 Cell Division
Tpic 1: Cell Bilgy (Teacher) 1.6 Essential Idea: Cell divisin is essential but must be cntrlled. 1.6 Cell Divisin Why d cells divide: - Sa:Vl Rati - Allws fr grwth f the rganism - Allws fr cell differentiatin
More information2017 CMS Web Interface
CMS Web Interface PREV-6 (NQF 0034): Clrectal Cancer Screening Measure Steward: NCQA Web Interface V1.0 Page 1 f 18 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE SAMPLING INFORMATION... 4 BENEFICIARY
More informationOriginal Policy Date 12:2013
MP 5.01.18 Xlair (Omalizumab) Medical Plicy Sectin Prescriptin Drugs Issu12:2013e 4:2006 Original Plicy Date 12:2013 Last Review Status/Date Lcal plicy/12:2013 Return t Medical Plicy Index Disclaimer Our
More informationReference: Patient C. Jeff KXXXXXX Date of Birth: 2/13/61
Reference: Patient C Jeff KXXXXXX Date f Birth: 2/13/61 43 y.. W male wh presented n Feb 16, 2004 with c/c f Adrenal Carcinma, initially diagnsed in September 2003, status pst surgical resectin in Oct
More informationErythropoiesis Stimulating Agents (ESAs): Aranesp (darbepoetin alfa) Related Medical Guideline Off-Label Use of FDA-Approved Drugs and Biologicals
(Subcutaneus/Intravenus) Last Review Date: January 1, 2019 Number: MG.MM.PH.80 *NON-DIALYSIS* Medical Guideline Disclaimer C All rights reserved. The treating physician r primary care prvider must submit
More informationIntravenous Vancomycin Use in Adults Intermittent (Pulsed) Infusion
Backgrund This plicy cvers the use f intravenus vancmycin prescribed as an intermittent (pulsed) infusin. This can be used fr treatment r prphylaxis. Evidence supprting this guidance is detailed belw.
More informationSection 5. Study Procedures
Sectin 5. Study Prcedures 5.1 Visit Lcatins... 1 5.2 Eligibility Determinatin... 1 5.3 Screening Visit... 2 5.3.1 Screening and Enrllment Timeframe... 2 5.3.2 Screening Visit Prcedures... 2 5.3.3 Screening
More information2018 Medical Association Poster Symposium Guidelines
2018 Medical Assciatin Pster Sympsium Guidelines Overview The 3 rd Annual student-run Medical Assciatin f the State f Alabama Research Sympsium will take place n Friday and Saturday, April 13-14 at the
More informationTHROUGH 1979, immunosuppressive
Five-Year Survival After Liver Transplantatin THROUGH 1979, immunsuppressive therapy fr liver transplantatin at ur center was with aathiprine (r cyclphsphamide) and sterids, t which antilymphcyte glublin
More informationSUMMACARE COMMERCIAL MEDICATION REQUEST GUIDELINES. ANTI-OBESITY AGENTS Generic Brand HICL GCN Exception/Other QSYMIA 32515, 32744, 32746, 32745
Generic Brand HICL GCN Exceptin/Other NALTREXONE CONTRAVE ER 41389 /BUPROPION LORCASERIN BELVIQ 34733 PHENTERMINE PHENTERMINE 20691 20692 20693 20713 PHENTERMINE LOMAIRA 20715 PHENTERMINE/TO PIRAMATE GUIDELINES
More informationWidening of funding restrictions for rituximab and eltrombopag
20 February 2014 Widening f funding restrictins fr rituximab and eltrmbpag PHARMAC is pleased t annunce the apprval f prpsals t widen the restrictin n rituximab use in DHB hspitals and expand the funding
More informationPBTC-045: Abstract and Schema
PBTC-045: A Safety and Preliminary Efficacy trial of MK-3475 (pembrolizumab; anti-pd-1) in Children with recurrent, progressive or refractory high-grade gliomas (HGG) and DIPGs Abstract and Schema This
More informationWaterloo Wellington Rehabilitative Care System Integrated Care Pathway for STROKE Stream of Care HYPERACUTE URGENT TIA and SECONDARY STROKE PREVENTION
Waterl Wellingtn Rehabilitative Care System Integrated Care Pathway fr STROKE Stream f Care HYPERACUTE URGENT TIA and SECONDARY STROKE PREVENTION Care Setting Activity Patients wh present t a cmmunity
More informationProtocol Abstract and Schema
Protocol Abstract and Schema This is a phase I/II study to determine: 1) the maximum tolerated dose (MTD) or recommended phase II dose of ABT-888 in combination with radiation therapy, and 2) the efficacy
More informationMedical Policy Title: HDC & Autologous ARBenefits Approval: 02/08/2012
Medical Plicy Title: HDC & Autlgus ARBenefits Apprval: 02/08/2012 Stem&/r Prgenitr Cell Supprt, Germ Cell Tumrs Effective Date: 01/01/2013 Dcument: ARB0416:01 Revisin Date: 10/24/2012 Cde(s): 38230, Bne
More informationReliability and Validity Plan 2017
Reliability and Validity Plan 2017 Frm CAEP The principles fr measures used in the CAEP accreditatin prcess include: (a) validity and reliability, (b) relevance, (c) verifiability, (d) representativeness,
More informationPROCEDURAL SAFEGUARDS NOTICE PARENTAL RIGHTS FOR PRIVATE SCHOOL SPECIAL EDUCATION STUDENTS
PROCEDURAL SAFEGUARDS NOTICE PARENTAL RIGHTS FOR PRIVATE SCHOOL SPECIAL EDUCATION STUDENTS INTRODUCTION This ntice prvides an verview f the parental special educatin rights, smetimes called prcedural safeguards
More informationIntravenous Vancomycin Use in Adults Intermittent (Pulsed) Infusion
Intravenus Vancmycin Use in Adults Intermittent (Pulsed) Infusin Backgrund This plicy cvers the use f intravenus vancmycin prescribed as an intermittent (pulsed) infusin. This can be used fr treatment
More information2018 CMS Web Interface
PREV-13: Statin Therapy fr the Preventin and Treatment f Cardivascular Disease CMS Web Interface PREV-13: Statin Therapy fr the Preventin and Treatment f Cardivascular Disease Measure Steward: CMS CMS
More informationctdna-guided Change of Therapy Improves Quality of Life of a Lung Cancer Patient
CASE STUDY ctdna-guided Change f Therapy Imprves Quality f Life f a Lung Cancer Patient Quick Summary Tripti Vasudev*, aged 61 years, was diagnsed with NSCLC. Genetic analysis revealed the presence f an
More informationHealth Screening Record: Entry Level Due: August 1st MWF 150 Entry Year
Health Screening Recrd: Entry Level MIDWIFERY EDUCATION PROGRAM HEALTH SCREENING REQUIREMENTS (Rev. June 2017) 1. Hepatitis B: Primary vaccinatin series (3 vaccines 0, 1 and 6 mnths apart), plus serlgic
More informationAbstract and Schema. Phase 1 and Pharmacokinetic Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma
Abstract and Schema Phase 1 and Pharmacokinetic Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma Description and Rationale: Low grade gliomas are among the most common primary CNS
More informationPolicy Guidelines: Genetic Testing for Carrier Screening and Reproductive Planning
Plicy Guidelines: Genetic Testing fr Carrier Screening and Reprductive Planning Cntents Overview... 1 Cverage guidelines... 2 General cverage guidelines... 2 Rutine carrier screening... 2 Carrier screening
More informationGUIDANCE DOCUMENT FOR ENROLLING SUBJECTS WHO DO NOT SPEAK ENGLISH
GUIDANCE DOCUMENT FOR ENROLLING SUBJECTS WHO DO NOT SPEAK ENGLISH Aurra Health Care s Research Subject Prtectin Prgram (RSPP) This guidance dcument will utline the prper prcedures fr btaining and dcumenting
More informationPennsylvania Guidelines on the Use of Opioids to Treat Chronic Noncancer Pain
Pennsylvania Guidelines n the Use f Opiids t Treat Chrnic Nncancer Pain Chrnic pain is a majr health prblem in the United States, ccurring with a pintprevalence f abut ne-third f the US ppulatin.(1) Mre
More informationRelated Policies None
Medical Plicy MP 3.01.501 Guidelines fr Cverage f Mental and Behaviral Health Services Last Review: 8/30/2017 Effective Date: 8/30/2017 Sectin: Mental Health End Date: 08/19/2018 Related Plicies Nne DISCLAIMER
More informationObesity/Morbid Obesity/BMI
Obesity/mrbid besity/bdy mass index (adult) Obesity/Mrbid Obesity/BMI Definitins and backgrund Diagnsis cde assignment is based n the prvider s clinical judgment and crrespnding medical recrd dcumentatin
More informationVolume Measurement at CT
Vlume Measurement at CT Staging and Assessment f Respnse with Quantitative CT Lawrence Schwartz, MD Department f Radilgy Clumbia University Cllege f Physicians and Surgens LSCHWARTZ@COLUMBIA.EDU Recmmendatins
More informationMy Symptoms and Medical History for Adult Chronic Immune Thrombocytopenia (ITP)
My Symptms and Medical Histry fr Adult Chrnic Immune Thrmbcytpenia (ITP) Call t talk t a registered nurse 1-855-7Nplate (1-855-767-5283), Mnday Friday, 9:00 AM 9:00 PM ET Indicatin Nplate is a man-made
More informationImproving Surveillance and Monitoring of Self-harm in Irish Prisons
HSE Mental Health Divisin Stewart s Hspital, Palmerstwn, Dublin 20 Tel: 01 6201670 Email: inf@nsp.ie www.nsp.ie Imprving Surveillance and Mnitring f Self-harm in Irish Prisns Prject Scpe Dcument 8 th June
More informationJefferies 2014 Global Healthcare Conference. June 3, 2014
Jefferies 2014 Glbal Healthcare Cnference June 3, 2014 Frward Lking Statements This presentatin cntains certain frward lking statements relating t the cmpany s financial results, business prspects and
More informationDiabetes: HbA1c Poor Control (NQF 0059)
Diabetes: HbA1c Pr Cntrl (NQF 0059) EMeasure Name Diabetes: HbA1c Pr Cntrl EMeasure Id Pending Versin Number 1 Set Id Pending Available Date N infrmatin Measurement January 1, 20xx thrugh Perid December
More informationTriumeq (abacavir, dolutegravir and lamivudine) Product Backgrounder for US Media
Triumeq (abacavir, dlutegravir and lamivudine) Prduct Backgrunder fr US Media What is Triumeq and wh is Triumeq fr? Triumeq (abacavir 600mg, dlutegravir 50mg and lamivudine 300mg) is the first dlutegravir-based
More informationGuideline for the use of granulocyte-colony stimulating factor (G-CSF) in adult oncology and haematology patients
Cumbria, Nrthumberland, Tyne & Wear Area Team Guideline fr the use f granulcyte-clny stimulating factr (G-CSF) in adult nclgy and haematlgy patients Dcument Cntrl Prepared By Issue Date Apprved By Review
More informationGuideline Number: NIA_CG_301 Last Revised Date: October 2014 Responsible Department: Implementation Date: October 2014 Clinical Operations
Natinal Imaging Assciates, Inc. Clinical guidelines PARAVERTEBRAL FACET JOINT INJECTIONS OR BLOCKS CPT Cdes: Cervical Thracic Regin: 64490 (+ 64491, +64492), 0213T (+0214T, +0215T) Lumbar Sacral Regin:
More informationContinuous Positive Airway Pressure (CPAP) and Respiratory Assist Devices (RADs) including Bi-Level PAP
Cntinuus Psitive Airway Pressure (CPAP) and Respiratry Assist Devices (RADs), Including Bi-Level PAP Benefit Criteria t Change fr Texas Medicaid Effective March 1, 2017 Overview f Benefit Changes Benefit
More informationPROVIDER ALERT. Comprehensive Diagnostic Evaluation (CDE) Guidelines to Access the Applied Behavior Analysis (ABA) Benefit.
Cmprehensive Diagnstic Evaluatin (CDE) Guidelines t Access the Applied Behavir Analysis (ABA) Benefit May 5, 2017 Clinical infrmatin that utlines medical necessity is required t supprt the need fr initial
More informationImplementation of G6PD testing and radical cure in P. vivax endemic countries: considerations
Implementatin f G6PD testing and radical cure in P. vivax endemic cuntries: cnsideratins Malaria Plicy Advisry Cmmittee Geneva, Switzerland 16-18 September 2015 1 WHO Guidelines n Radical Cure WHO guidelines
More informationHEDIS. Healthcare Effectiveness Data & Information Set (HEDIS ) QUALITY MANAGEMENT PROGRAM SECTION 8
HEDIS Healthcare Effectiveness Data & Infrmatin Set (HEDIS ) The HEDIS â audit cntains a cre set f perfrmance measures that prvide infrmatin abut custmer satisfactin, specific health care measures, and
More informationNCT ClinialTrials.gov Identifier: sanofi-aventis. Sponsor/company: PRIST_L_ Study Code: PRISTINAMYCIN Date: Generic drug name:
These results are supplied fr infrmatinal purpses nly. Prescribing decisins shuld be made based n the apprved package insert in the cuntry f prescriptin Spnsr/cmpany: sanfi-aventis ClinialTrials.gv Identifier:
More informationChimeric Antigen Receptor T cell Therapy (CAR-T)
Applies t all prducts administered r underwritten by Blue Crss and Blue Shield f Luisiana and its subsidiary, HMO Luisiana, Inc.(cllectively referred t as the Cmpany ), unless therwise prvided in the applicable
More informationPICO question In patients with glomerulonephritis what are patient preferences and values for immunosuppressive and non-immunosuppressive therapy?
KDIGO GN Guideline update Evidence summary Patient preferences fr glmerulnephritis treatment PICO questin In patients with glmerulnephritis what are patient preferences and values fr immunsuppressive and
More information